Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing TherapyLai, Chow Yee MBBS; Pettit, Tristan FRACPJournal of Pediatric Hematology/Oncology: November 2019 - Volume 41 - Issue 8 - p 620–623 doi: 10.1097/MPH.0000000000001243 Clinical and Laboratory Observations Buy Abstract Author InformationAuthors Article MetricsMetrics In this report, we present a young infant with multisystem Langerhans cell histiocytosis, who after cladribine and cytarabine salvage treatment developed immune thrombocytopenia (IT). On review of the literature, there were no previous reports of Langerhans cell histiocytosis–associated IT. Treatment of the IT with intravenous immunoglobulin and oral corticosteroids was unsuccessful. Eltrombopag, in combination with a 4-day course of dexamethasone was commenced as second-line therapy. Platelet recovery occurred 10 days after initiation of eltrombopag. The immune thrombocytopenia remains in long-term remission despite cessation of eltrombopag. Eltrombopag was safe and well tolerated. Children’s Haematology and Oncology Centre, Christchurch Hospital, Canterbury District Health Board, Christchurch, New Zealand The authors declare no conflict of interest. Reprints: Chow Yee Lai, MBBS, Children’s Haematology and Oncology Centre, Christchurch Hospital, Canterbury District Health Board, Private Bag 4710, Christchurch 8140, New Zealand (e-mail: firstname.lastname@example.org). Received February 8, 2018 Accepted May 11, 2018 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.